ORION CORPORATION STOCK EXCHANGE RELEASE 2 SEPTEMBER 2019 at 9.30 EEST
135,000 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 135,000 A shares have been converted into 135,000 B shares. The conversion has been entered into the Trade Register on 2 September 2019.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 36,686,579 A shares and 104,571,249 B shares. The number of votes of the company's shares is after the conversion 838,302,829
Orion Corporation
| Jari Karlson CFO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
